Analysis of an Expanded Targeted Early Cytomegalovirus Testing Program.

OBJECTIVE: Determine the detection rate from an expanded targeted early cytomegalovirus (CMV) testing program implemented from a large healthcare system (Intermountain Healthcare, IHC). STUDY DESIGN: Retrospective review. SETTING: Tertiary medical center. METHODS: An electronic system was modified to include indications for testing whenever a provider placed an order for CMV testing. A retrospective analysis of this database was performed. RESULTS: From March 1, 2021 to August 31, 2022, there were 3450 (8.8%) patients who underwent CMV testing out of 39,245 total live births within the IHC system. Since the formal implementation of this program in 2019, annual CMV testing has increased almost 10-fold: 2668 CMV tests were performed in 2021 compared to 289 CMV tests in 2015. The most frequent indication for congenital CMV (cCMV) testing was small for gestational age (SGA) (68.2%), followed by macrocephaly (13.5%), an abnormal hearing test (5.0%), and microcephaly (4.4%). Fourteen cCMV-infected infants were diagnosed all of them meeting the criteria for symptomatic cCMV. The most common indication resulting in a positive diagnosis was those who presented with SGA (n = 10 patients). The positivity rate would result in a prevalence of 35.7 symptomatic cCMV cases diagnosed per 100,000 live births, numbers comparable to those expected for universal cCMV screening. CONCLUSION: An expanded targeted early cCMV testing program may improve detection rates of symptomatic cCMV cases and should be considered as a feasible alternative approach to universal or hearing-targeted early CMV testing.

Molecular characterization of Streptococcus pyogenes isolates collected during periods of increased acute rheumatic fever activity in Utah.

BACKGROUND: Salt Lake City, Utah has seen a continuing resurgence of rheumatic fever (RF) since 1985. METHODS: emm genotyping and multilocus sequence typing of streptococcal isolates from periods of increased RF activity were performed. RESULTS: Multiple genotypes were present during 1985 and 1998, two peak years of RF activity, and in 1992, a year with reduced RF activity. emm3 and emm18.1 were present in 1985 and 1998, but not in 1992. Two other emm types, 12 and L28, were significantly elevated in 1998 (a peak RF year) over 1992 (a non-peak RF year). Allelic profiles for the emm3 and emm18.1 isolates exhibited clonality. CONCLUSIONS: During years of increased RF activity multiple emm types, including emm18.1 and emm3, were circulating in the community. During a year of decreased RF activity, emm3 and emm18.1 genotypes were absent. The clonality of the emm3 and emm18.1 types suggests that specific clones of both types are important in the resurgence of RF during these peak years. Two other genotypes, emm12 and emmL28, may also be associated with the persistence of RF in the Salt Lake City, UT area.

Herpes Simplex Virus Infections of the Newborn.

Herpes simplex virus (HSV) infection in newborns is an important cause of death and permanent neurodevelopmental disability among young children. Neonatal HSV infections can be categorized as 1) mucocutaneous (skin-eyes-mouth), 2) disseminated, or 3) encephalitic. In addition, congenital HSV infection, a distinct clinical syndrome, accounts for approximately 5% of HSV infections identified in the neonatal period. Polymerase chain reaction greatly enhances the clinician's ability to diagnosis HSV infections, but as many as 25% of infants with neonatal HSV encephalitis have negative polymerase chain reaction studies of cerebrospinal fluid. Infants with proven or suspected HSV infections should receive acyclovir 60 mg/kg/day divided every 8 hours for 14 days if disease is restricted to the skin, eyes, or mucous membranes and for 21 days if the infant has disseminated infection or encephalitis. The benefit of long-term suppression therapy after completion of the initial treatment regimen has not been established definitively. Despite therapy with acyclovir, the best available anti-HSV drug, a substantial number of HSV-infected infants with disseminated infections or encephalitis die or have long-term neurodevelopmental sequelae.

Large vancomycin overdose in two premature infants with minimal toxicity.

Two premature infants received 10-fold overdoses of vancomycin with resulting peak plasma concentrations > 300 microg/mL. Discontinuation of vancomycin and watchful waiting were employed, with no specific intervention to accelerate vancomycin clearance. Plasma vancomycin concentration < 40 microg/mL was attained at < 48 hours in one infant and < 72 hours in the other. Although one infant sustained a transient increase in serum creatinine to 1.4 mg/dL, no further evidence of renal, auditory, or other toxicity was detected in either infant acutely or long term. Contemporary preparations of vancomycin appear much less toxic than earlier formulations. Aggressive and invasive interventions to hasten clearance may be unnecessary following overdose in infants with normal or near-normal basal renal function, although careful surveillance for clearance and toxic effects still appear warranted.